teal

QuarterWatch™ Reports

An independent perspective on emerging drug risks

QuarterWatch™ is published four times a year as a public service to provide an independent perspective on emerging drug risks. This scientific publication uses as its primary source recently released reports submitted to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).

Browse Issues

Anticoagulants leading drug safety problem reported directly to FDA • Three anti-TNF agents dominate manufacturer reports of new, serious injuries • Fentanyl patches (DURAGESIC) prominent in product problems and medication errors • Lower limb fractures when taking alendronate (FOSAMAX) a major reported adverse event
Varying signals for pancreatitis, hypersensitivity, and cancer • Three oral versus two injectable agents compared • Link to human and animal studies of the pancreas
Finasteride (PROPECIA, PROSCAR) and possibly persistent sexual side effects • Methylphenidate patch (DAYTRANA) and product problems • Update on anticoagulants dabigatran (PRADAXA) and rivaroxaban (XARELTO)
The most frequently identified suspect drugs in direct reports to the FDA were the anticoagulants dabigatran (PRADAXA) and warfarin (COUMADIN), showing that inhibiting clotting ranks among the highest risk of all drug treatments.
Strong signal for serious bleeding with the new anticoagulant drug dabigatran (PRADAXA) • Reports of brain damage associated with metoclopramide (REGLAN) • A review of quarterly data for the five most widely prescribed drugs in the US